PHARMACOLOGY IV – HEADACHE THERAPEUTICS PRACTICE TEST (SAMPLE)

STUDY GUIDE

SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://pharm4headachetherapeutics.examzify.com

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. Which statement best describes riboflavin therapy in migraine prevention?

A. It is associated with frequent severe adverse effects.

B. It is expensive and not preferred.

C. It is well tolerated.

D. It is contraindicated in migraine.

2. What is the mechanism of action of ergotamines?

A. Dopamine receptor antagonist

B. CGRP receptor antagonist

C. Nonspecific serotonin receptor agonist and vasoconstrictor

D. Selective 5-HT1B/1D receptor agonist

3. Which of the following describes a common adverse effect of onabotulinumtoxin A for migraine prophylaxis?

A. Neck pain and headache

B. Severe hepatotoxicity

C. Tremor and weight gain

D. Seizures

4. How do CGRP monoclonal antibodies become prescribed in terms of administration?

A. Intramuscular injections daily

B. Subcutaneous injections at regular intervals (monthly or quarterly) depending on agent

C. Oral tablets daily

D. Intravenous infusions weekly

5. Concomitant use of ergot derivatives with triptans is contraindicated because of the risk of what?

A. There is no risk when combined with triptans.

B. Increased risk of vasospasm.

C. Safe use in pregnancy.

D. It reduces the efficacy of triptans.

6. Which of the following is an oral CGRP antagonist approved for migraine prevention?

A. Rimegepant

B. Atogepant (Qulipta)

C. Fremanezumab

D. Divalproex

7. Which statement about DHE administration is correct?

A. It is given orally.

B. It is given intramuscularly.

C. It is given IV or nasal, sometimes with IV metoclopramide and fluids.

D. It is inhaled.

8. In acute migraine management, triptans are commonly used in combination with which of the following to enhance efficacy?

A. Triptans must always be used with NSAIDs.

B. They should never be used with NSAIDs.

C. Combining triptans with NSAIDs can be beneficial.

D. They must be used with antidepressants.

9. Which therapy is primarily preventive, requiring injections at regular intervals?

A. Gepants are preventive therapies with weekly injections.

B. Lasmiditan is preventive therapy.

C. Triptans are preventive therapy.

D. CGRP monoclonal antibodies are preventive therapies with weekly or monthly injections.

10. What is the typical timeframe to evaluate the effectiveness of a preventive therapy?

A. About 2–3 months; adjust regimen if insufficient response

B. Within 24 hours

C. 6 weeks

D. 12 months

Answers

1. C
2. C
3. A
4. B
5. B
6. B
7. C
8. C
9. B
10. A

Explanations

1. Which statement best describes riboflavin therapy in migraine prevention?

A. It is associated with frequent severe adverse effects.

B. It is expensive and not preferred.

C. It is well tolerated.

D. It is contraindicated in migraine.

Riboflavin therapy for migraine prevention is characterized by a favorable safety profile and good tolerability. When given in high daily doses (around 400 mg), it is generally well tolerated with few and mild adverse effects. The most common notable effect is harmless yellow-orange urine from excreted vitamin B2; occasional mild GI upset can occur, but serious adverse effects are rare. Its safety, low risk of interactions, and low cost contribute to it being a preferred preventive option for many patients. This makes the statement that it is well tolerated the best description.

2. What is the mechanism of action of ergotamines?

A. Dopamine receptor antagonist

B. CGRP receptor antagonist

C. Nonspecific serotonin receptor agonist and vasoconstrictor

D. Selective 5-HT1B/1D receptor agonist

Ergotamines work by acting as nonselective serotonin receptor agonists, producing vasoconstriction of cranial and other blood vessels. They stimulate multiple serotonin receptors, not just one subtype, with a prominent effect on receptors involved in vascular tone. This constriction reduces the pulsatile dilation and neurogenic inflammation thought to contribute to migraine symptoms, providing relief. Because they're not highly selective, ergotamines also interact with other receptor systems (such as alpha-adrenergic and dopaminergic receptors), which helps explain their potent vasoconstrictive effects and broader side effects. This distinguishes them from drugs that are designed to be selective 5-HT1B/1D receptor agonists, like the triptans, which target a specific receptor subset to relieve migraine. In short, ergotamines are nonspecific serotonin receptor agonists with vasoconstrictive effects, rather than a dopamine antagonist, a CGRP receptor antagonist, or a strictly selective 5-HT1B/1D receptor agonist.

3. Which of the following describes a common adverse effect of onabotulinumtoxin A for migraine prophylaxis?

A. Neck pain and headache

B. Severe hepatotoxicity

C. Tremor and weight gain

D. Seizures

When using onabotulinumtoxin A for chronic migraine prevention, the side effects most often come from the local effect on nearby muscles where the injections are given. Injecting into pericranial and neck muscles can cause muscle soreness and temporary changes in muscle tone, so neck pain and headache are commonly reported after treatment. In contrast, severe hepatotoxicity, tremor with weight gain, or seizures are not typical adverse effects of this localized therapy. Therefore, neck pain and headache best describe a common adverse effect.

4. How do CGRP monoclonal antibodies become prescribed in terms of administration?

A. Intramuscular injections daily

B. Subcutaneous injections at regular intervals (monthly or quarterly) depending on agent

C. Oral tablets daily

D. Intravenous infusions weekly

The main idea is that CGRP monoclonal antibodies are given by subcutaneous injections at regular intervals, not daily pills or weekly infusions. Most of these agents are dosed monthly by subcutaneous injection, with fremanezumab offering either monthly or quarterly schedules depending on the regimen. An important exception is eptinezumab, which is given by intravenous infusion every 12 weeks. So the typical prescription pattern is subcutaneous injections at monthly or quarterly intervals, depending on the specific agent.

5. Concomitant use of ergot derivatives with triptans is contraindicated because of the risk of what?

A. There is no risk when combined with triptans.

B. Increased risk of vasospasm.

C. Safe use in pregnancy.

D. It reduces the efficacy of triptans.

The risk being tested is the potential for dangerous vasospasm from combining two drugs that both constrict blood vessels through serotonin receptor activity. Triptans activate 5-HT1B/1D receptors on cranial vessels, causing vasoconstriction and reducing CGRP-mediated pain signaling. Ergot derivatives are nonspecific serotonergic agents (and also interact with other receptors) that produce strong vasoconstriction. When used together, their effects can sum to excessive constriction of cerebral and peripheral arteries, increasing the chance of ischemia or infarction in the brain, heart, or extremities. That's why this combination is contraindicated. It isn't a matter of safety in pregnancy, nor does it reduce efficacy of triptans; there is a real added risk of vasospasm.

6. Which of the following is an oral CGRP antagonist approved for migraine prevention?

A. Rimegepant

B. Atogepant (Qulipta)

C. Fremanezumab

D. Divalproex

The key idea is that blocking CGRP signaling with an oral antagonist can prevent migraine by reducing the trigeminovascular activation that drives attacks. An oral small molecule that directly blocks the CGRP receptor fits this role for prevention. Atogepant (Qulipta) is specifically developed and approved for migraine prevention in adults as an oral medication. By antagonizing the CGRP receptor, it prevents CGRP from triggering the vasodilation and pain pathways involved in migraine, which translates into fewer migraine days and attacks when used chronically. Rimegepant is also an oral CGRP receptor antagonist, but it has been most prominently used for acute treatment of migraine, with preventive labeling added later in some settings. The question's focus on an oral agent approved for prevention aligns most directly with atogepant, which is the drug approved explicitly for preventive use. Fremanezumab is a CGRP-targeting monoclonal antibody given by injection for prevention, not an oral medication, so it doesn't meet the "oral" criterion. Divalproex is a valproate used for migraine prophylaxis but not a CGRP antagonist. So the best choice is the oral CGRP receptor antagonist approved for prevention, which is atogepant.

7. Which statement about DHE administration is correct?

A. It is given orally.

B. It is given intramuscularly.

C. It is given IV or nasal, sometimes with IV metoclopramide and fluids.

D. It is inhaled.

Dihydroergotamine has very limited and variable oral absorption, so it isn't given by mouth. The effective routes for acute migraine treatment are intravenous or intranasal, with the nasal form providing rapid relief and IV administration used in clinical settings. To improve tolerability and, in the IV route, absorption, an antiemetic like metoclopramide may be given with fluids. Therefore, IV or nasal administration, sometimes with IV metoclopramide and fluids, is the correct approach. The other routes listed (oral, intramuscular, inhaled) are not standard for DHE in this context.

8. In acute migraine management, triptans are commonly used in combination with which of the following to enhance efficacy?

A. Triptans must always be used with NSAIDs.

B. They should never be used with NSAIDs.

C. Combining triptans with NSAIDs can be beneficial.

D. They must be used with antidepressants.

Combining therapies that target different parts of the migraine pain pathway can improve overall relief. Triptans act by constricting cranial blood vessels and dampening the trigeminal nerve's release of inflammatory peptides, while NSAIDs reduce inflammation and prostaglandin-mediated sensitization. Using an NSAID with a triptan can speed up relief and reduce the chance of pain returning within 24 hours, a benefit supported by clinical trials showing better outcomes with the combination than with either agent alone. So, in practice, adding an NSAID to a triptan for acute migraine can enhance efficacy. Always tailor to the patient's risks (GI, kidney, cardiovascular) and individual response, as this combination isn't mandatory for every case.

9. Which therapy is primarily preventive, requiring injections at regular intervals?

A. Gepants are preventive therapies with weekly injections.

B. Lasmiditan is preventive therapy.

C. Triptans are preventive therapy.

D. CGRP monoclonal antibodies are preventive therapies with weekly or monthly injections.

Preventive migraine therapy delivered by injections at regular intervals is the class of CGRP monoclonal antibodies. These biologics block CGRP signaling (either the CGRP ligand or its receptor), which reduces the frequency of migraine attacks over time. They are given by subcutaneous injections on a regular schedule—monthly or every few months depending on the specific agent (for example, monthly for some, quarterly for others). This distinguishes them from Lasmiditan, which treats acute migraines and is taken as needed (oral), and from gepants, which are also used for acute treatment and taken orally. Triptans are likewise acute therapies. So the option describing CGRP monoclonal antibodies as preventive injections at regular intervals best fits the scenario.

10. What is the typical timeframe to evaluate the effectiveness of a preventive therapy?

A. About 2–3 months; adjust regimen if insufficient response

B. Within 24 hours

C. 6 weeks

D. 12 months

Preventive headache therapies work by gradually altering brain pathways, so they need time to show their full effect on attack frequency and severity. The typical trial duration to judge effectiveness is about 2–3 months at a therapeutic dose; if there isn't a meaningful reduction in migraine days or burden by then, the regimen should be adjusted or switched. Waiting only 24 hours belongs to acute treatment, not prevention. Six weeks may capture some early changes but usually isn't enough to determine full benefit, and waiting a full year would delay optimization and patient improvement.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://pharm4headachetherapeutics.examzify.com

We wish you the very best on your exam journey. You've got this!